Latest News from ASCO in Action

Latest News from ASCO in Action

April 17, 2014

On April 17, 2014, the U. S. Food and Drug Administration approved ofatumumab (Arzerra® Injection, for intravenous infusion; GlaxoSmithKline) in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.

April 17, 2014

The American Society of Clinical Oncology (ASCO) is urging the Centers for Medicare & Medicaid Services (CMS) to immediately correct inaccuracies in Medicare physician payment data released last week.

April 9, 2014

The American Society of Clinical Oncology (ASCO) is deeply concerned about today’s release of Medicare physician payment data. ASCO is committed to the delivery of high quality, high value care for all people with cancer in the United States. This data release solely focuses attention on the dollars paid to practices for the medical care and treatment of patients on Medicare, rather than contributing to the ongoing national conversation about value and quality in health care.

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.